Business Wire

FINEOS Achieves Unprecedented Client Go Live Success in 2020

28.1.2021 17:15:00 EET | Business Wire | Press release

Share

FINEOS Corporation (ASX:FCL) continues to demonstrate its long standing purpose to “help our clients care for the people they serve through the delivery of superior insurance technology” in 2020 with the completion of 8 new installations and 7 major upgrades of the FINEOS Platform. As a leading provider of core systems for life, accident and health insurers globally, FINEOS offers unparalleled core solutions that help carriers become more dynamic, scalable and competitive.

“We are pleased with our performance over the past year, especially given the challenges we all face in these times of COVID,” said Michael Kelly, CEO of FINEOS. “Many of our global clients are actively engaged in brand-new installations, version upgrades and platform migrations. This tells us that our clients see the value of our significant R&D investment made over the past 5 years and indeed are modernizing their core systems in support of their digital transformation. We are grateful to our clients and SI partners for the tremendous implementation and upgrade achievements over the past year.”

By upgrading to the SaaS-based FINEOS Platform, clients will reap the benefits of a more modern and comprehensive unified system for integrated absence, group and voluntary benefits.

“The FINEOS Platform is purpose built to support the Employee Benefits market and therefore provides several advantages to our clients over repurposed P&C core systems,” said Chuck Johnston, CMO of FINEOS. “As a result, our clients enjoy easier installations and upgrades. What’s more, innate policy and customer management capabilities that exist across the entire FINEOS Platform provide consistent product information as well as powerful, frictionless process and workflows across the platform. These foundational capabilities are distinctive to the FINEOS Platform market offerings from claims to Integrated Disability and Absence Management (IDAM) to the full FINEOS AdminSuite which enables clients to move to quote to claim on one system.”

Demonstrated client success metrics include:

  • 40% improvement in staff satisfaction in billing and policy admin
  • 27% reduction in disability duration
  • 10% increase in client on-time contact
  • 25% increase in claim settlements per day
  • 12% improvement in RTW (Return to Work)
  • 93% reduction for claims acceptance time: now accepted within five days of an accident, down from seventy

Since the start of the COVID-19 pandemic, Employee Benefits carriers in North America and protection schemes across the globe have seen increased demand from their customers for new products, remote functionality, and faster processing times that cannot be achieved with legacy systems.

The value of the FINEOS Platform with excellent client support is evident in the company’s long-term partnerships. “Our partnership with FINEOS continues to grow and we are realizing benefits from the FINEOS system, including streamlined processes which enable our managers to focus on providing excellent outcomes to QSuper members,” said Phil Frazer, CEO of QInsure, Australia. “We are excited to continue our partnership with FINEOS to help support our organization’s agility, digital customer experience and our service excellence.”

In North America, where claims and paid leave laws continue to reverberate with change due to COVID, the necessity for carriers to embrace Integrated Disability and Absence Management (IDAM) remains a critical path to future success. Throughout 2020, FINEOS continued to focus on integrated absence management as a core capability, helping carriers simplify the complex process of managing absence to improve engagement and user experience. As the industry leader for core software, FINEOS plans to raise the industry standard in 2021 even further by continually expanding the FINEOS Platform for Employee Benefits.

“Insurers need technology solutions to meet the increased expectations for customer experience and to increase efficiencies and outcomes for key products like Disability and Absence Management,” says Nancy Casbarro, Vice President of Research and Consulting at Novarica. “They’re looking to solution providers like FINEOS for solutions that offer digital solutions for self-service, configurable policy administration, enrollment and claims capabilities all driving greater efficiency, reliable upgrades and long-term system lifecycle support.”

About FINEOS Corporation

FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.

The FINEOS Platform provides core administration capabilities including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as FINEOS AdminSuite, an end-to-end core administration suite.

For more information, visit www.FINEOS.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Victoria Jamison
Marketing Manager
FINEOS Corporation
+ 353 1 639 9700
victoria.jamison@FINEOS.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye